Other researchers also demonstrated that TTFields combined with anti-PD1/anti-CTLA-4/anti-PD-L1 therapy can significantly reduce tumor volume and increase the infiltration of cytotoxic T lymphocytes and memory CD8+ T cells in the tumor microenvironment [47]. This evidence concerns the gene CTLA4 and neoplasm.